Ketolides Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The ketolides market size has grown steadily in recent years. It will grow from $3.22 billion in 2024 to $3.35 billion in 2025 at a compound annual growth rate (CAGR) of 4.1%. The growth in the historic period can be attributed to increasing prevalence of infectious diseases, growing consumption of antibiotics, demand for effective and convenient treatments for infectious diseases, government initiatives.

The ketolides market size is expected to see steady growth in the next few years. It will grow to $4.04 billion in 2029 at a compound annual growth rate (CAGR) of 4.8%. The growth in the forecast period can be attributed to investments in research and development activities for ketolides, growing number of screening programs for infectious diseases, incremental healthcare spending growing awareness of antimicrobial stewardship. Major trends in the forecast period include innovative treatments for infectious diseases, development of targeted therapies, advancements in diagnosis and treatment of infectious diseases, development of new ketolide formulations.

The rising prevalence of infectious diseases is expected to drive the growth of the ketolides market. Infectious diseases, caused by pathogens such as bacteria, viruses, fungi, or parasites, can spread from person to person, leading to a variety of health complications. Tuberculosis (TB) is one example of an infectious disease for which ketolides are being evaluated due to their potent intracellular activity, which is crucial for treating TB. For instance, in February 2024, GOV.UK reported that cases of tuberculosis in England increased by 10.7% in 2023, rising from 4,380 in 2022 to 4,850. As infectious diseases like tuberculosis continue to rise, the demand for effective treatments, including ketolides, is expected to grow.

The expansion of the healthcare industry is expected to drive the growth of the ketolides market. The healthcare industry encompasses various sectors focused on curing, preventing, rehabilitating, and providing palliative care for patients. As the healthcare sector grows, it plays a critical role in the development and distribution of ketolides by supporting research, clinical trials, and regulatory processes to assess their safety and effectiveness. Additionally, the healthcare industry ensures that ketolides are administered securely and efficiently to patients. For example, in May 2023, the American Health Care Association reported an increase in the number of hospitals in the U.S., rising from 6,093 in 2022 to 6,129. This growth in healthcare infrastructure supports the ongoing development and adoption of treatments like ketolides, thereby fueling market expansion.

The leading companies within the ketolides market are strongly committed to pioneering innovative drugs and treatment approaches, with the aim of gaining a competitive edge and maintaining their market position. For instance, AliquantumRx Inc., a US-based biotechnical research company, which, in June 2023, celebrated the approval of a patent by the United States Patent and Trademark Office (USPTO), a key agency under the Department of Commerce. This patent, titled 'salts and polymorphs of cethromycin for the treatment of bacterial and protozoan disease,' pertains to cethromycin, a ketolide antibiotic that demonstrates effectiveness against various infectious diseases caused by both bacteria and protozoa. These conditions encompass malaria, babesiosis, toxoplasmosis, diarrhea, and more. Notably, this newly granted patent significantly expands the possibilities for the use of cethromycin, potentially lowering the barriers to its commercialization and facilitating its application in treating a broader range of diseases.

The ketolides market is witnessing growth, primarily attributed to the increasing prevalence of chronic sinusitis. Chronic sinusitis is characterized by persistent inflammation in the sinus cavities around the nasal passages. Ketolides, a class of antibiotics with immunomodulatory and anti-inflammatory properties, find application in the treatment of various medical conditions. Given that chronic sinusitis involves inflammation of the sinuses, ketolides play a role in mitigating this inflammation and alleviating associated symptoms. For example, data from the US-based Centers for Disease Control and Prevention (CDC) as of January 2022 indicated that approximately 11.6% of adults in the United States had received diagnoses of sinusitis. Consequently, the expanding occurrence of chronic sinusitis serves as a driving force behind the growth of the ketolides market.

Major companies operating in the ketolides market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, GSK PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Shionogi & Company Limited, Dr. Reddys Laboratories Ltd., Taisho Pharmaceutical Co. Ltd., Glenmark Pharmaceuticals Ltd., Zhejiang Yongtai Technology Co. Ltd., Corden Pharma GmbH, Optimer Pharmaceuticals Inc., Vivimed Labs Limited, Wockhardt Ltd., Advanced Life Sciences Holdings Inc.

North America was the largest region in the ketolides market in 2024. The regions covered in ketolides report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the ketolides market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ketolides market consists of sales of solithera and ketek, arylalkyl and macrolactone rings. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Ketolides, a class of antibiotics within the macrolide group, are derived from erythromycin, a 14-membered macrolide. They are created by replacing the cladinose sugar with a keto-group and incorporating a cyclic carbamate group into the lactone ring structure. Ketolides exert their antibiotic effects by inhibiting protein synthesis, thus impeding the production of essential proteins vital for bacterial maintenance and survival.

The primary drugs falling under the ketolides category include telithromycin, cethromycin, and solithromycin. Telithromycin, a semi-synthetic antibiotic of the ketolide class, is deployed in the treatment of respiratory tract infections. These antibiotics find application in a range of conditions, including bronchitis, pneumonia, sinusitis, tonsillitis, and pharyngitis. They target various microorganisms such as Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Chlamydophila pneumoniae, and Mycoplasma pneumoniae. Ketolides are distributed through diverse channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others.

The ketolides market research report is one of a series of new reports that provides ketolides market statistics, including ketolides industry global market size, regional shares, competitors with a ketolides market share, detailed ketolides market segments, market trends and opportunities and any further data you may need to thrive in the ketolides industry. This ketolides market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.